Sw 13

The human ACC cell lines, NCI-H295R and SW-13, were acquired from Procell Life Science &Technology (Wuhan, China). SW-13 cells were maintained in Leibovitz's L-15, with 10% FBS and 1% P/S (Procell, CM-0451). NCI-H295R cells were maintained in DMEM/F12, with 6.25 μg/mL insulin, 6.25 ng/mL selenium, 6.25 μg/mL transferrin, 5.35 μg/mL linoleic acid, 10% FBS and 1% P/S (Procell, CM-0399).

Human ACC cell lines (SW13, NCI-H296R) were purchased from the Procell Life Science & Technology Co., Ltd. in Wuhan, China. The cell line was identified by the China Centre for Type Culture Collection in Wuhan, China. SW13 was incubated in DMEM medium (Gibco, China), supplemented with 10% fetal bovine serum (FBS) (Gibco, Australia) according to the ATCC instructions. NCI-H296R was grown and maintained in DMEM media supplemented with 1% insulin transferrin selenium (Gibco, China) and 2.5% Nu-Serum I (Gibco, China) in a standard humidified incubator at 37°C in a 5% CO₂ atmosphere. ACC and adjacent normal adrenal tissues (n = 8) were obtained from patients undergoing laparoscopic unilateral adrenalectomy at Zhongnan Hospital of Wuhan University. Two pathologists independently confirmed the histological diagnosis. All specimens were immediately fixed in 4% PFA (paraformaldehyde) and stored in liquid nitrogen. Prior to their operation, none of the patients enrolled in the study receive any treatment. The use of these ACC specimens was approved by the Ethics Committee at Zhongnan Hospital of Wuhan University, and informed consent was obtained from all patients.